Open Journal Systems

Cover Image

Hsp90 Inhibitors in Cancer

Hardik J Patel

Abstract


Hsp90 is a member of chaperone family responsible for maintaining cellular homeostasis by regulating proper folding of proteins into mature and functional form. In various cancers it is overexpressed and is responsible for chaperoning of oncogenic client proteins such as Her2, EGFR, Akt, ERK, mutant p53 etc. that are involved in cancer survival and metastasis signaling pathways.  Thus inhibition of Hsp90 has emerged as an important strategy in the treatment of cancer, where inhibition of Hsp90 function can lead to improper folding of oncogenic client proteins eventually leading to degradation of these client proteins. The proof of concept for clinical efficacy of Hsp90 inhibition is attesteted by advancement of numerous small molecule Hsp90 inhibitors in clinical trials for the treatment of various cancers. This mini-review discusses development of small molecule Hsp90 inhibitors into clinic and their current clinical status for the treatment of cancer.


Keywords


Hsp90 inhibitors, cancer chemotherapy, signaling, small molecule inhibitors

Full Text:

PDF

References


Trepel J, Mollapour M, Giaccone G, Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.

http://dx.doi.org/10.1038/nrc2887

PMid:20651736

Chiosis G, Vlenchik M, Kim J, Solit D: Hsp90: the vulnerable chaperone. . Drug Discuss Today 2004, 9:881-888.

http://dx.doi.org/10.1016/S1359-6446(04)03245-3

Zhang H, Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82:488-499.

http://dx.doi.org/10.1007/s00109-004-0549-9

PMid:15168026

Porter JR, Fritz CC, Depew KM: Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010, 14:412-420.

http://dx.doi.org/10.1016/j.cbpa.2010.03.019

PMid:20409745

Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH: ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO 1998, 17:4829–4836.

http://dx.doi.org/10.1093/emboj/17.16.4829

PMid:9707442 PMCid:PMC1170812

Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C, Robinson CV, Saibil HR, Pearl LH: Structure of an Hsp90–Cdc37–Cdk4 complex. Mol. Cell 2006, 23:697–707.

http://dx.doi.org/10.1016/j.molcel.2006.07.016

PMid:16949366

Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, Prodromou C, Pearl LH: Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex. Nature 2006, 440:1013–1017.

http://dx.doi.org/10.1038/nature04716

PMid:16625188

Hessling M, Richter K, Buchner J: Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 2009, 16:287-293.

http://dx.doi.org/10.1038/nsmb.1565

PMid:19234467

Shiau AK, Harris SF, Southworth DR, Agard DA: Structural analysis of E. coli Hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006, 127:329-340.

http://dx.doi.org/10.1016/j.cell.2006.09.027

PMid:17055434

Patel HJ, Modi S, Chiosis G, Taldone T: Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin. Drug Discov. 2011, 6:559-587.

http://dx.doi.org/10.1517/17460441.2011.563296

PMid:22400044 PMCid:PMC3293194

Janin YL: ATPase inhibitors of heat-shock protein 90, second season. Drug Discovery Today 2010, 15:342-353.

http://dx.doi.org/10.1016/j.drudis.2010.03.002

PMid:20230904

Whitesell L, Shifrin SD, Schwab G, Neckers LM: Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 1992, 52:1721-1728.

PMid:1551101

Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM: Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91:8324-8328.

http://dx.doi.org/10.1073/pnas.91.18.8324

PMid:8078881 PMCid:PMC44598

Prodromou C, Roe SM, O`Brien R, Ladbury JE, Piper PW, Pearl LH: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90:65-75.

http://dx.doi.org/10.1016/S0092-8674(00)80314-1

Supko JG, Hickman RL, Grever MR, Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36:305-315.

http://dx.doi.org/10.1007/BF00689048

PMid:7628050

Taldone T, Sun W, Chiosis G: Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 2009, 17:2225-2235.

http://dx.doi.org/10.1016/j.bmc.2008.10.087

PMid:19017562 PMCid:PMC2760286

Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig H-H, Sausville EA: In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 2005, 56:115-125.

http://dx.doi.org/10.1007/s00280-004-0939-2

PMid:15791458

Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, et al.: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23:4152-4161.

http://dx.doi.org/10.1200/JCO.2005.00.612

PMid:15961763

Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, et al.: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23:1078-1087.

http://dx.doi.org/10.1200/JCO.2005.09.119

PMid:15718306

Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, et al.: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 2005, 11:3385-3391.

http://dx.doi.org/10.1158/1078-0432.CCR-04-2322

PMid:15867239

Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, et al.: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 2007, 13:1775-1782.

http://dx.doi.org/10.1158/1078-0432.CCR-06-1863

PMid:17363532 PMCid:PMC3203693

Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C: A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res. 2006, 12.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, et al.: Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 2007, 25:5410-5417.

http://dx.doi.org/10.1200/JCO.2007.11.7960

PMid:18048823

Modi S, Stopeck AT, Linden HM, Solit DB, Chandarlapaty S, Rosen N, D'Andrea G, Dickler MN, Moynahan ME, Sugarman S, et al.: HSP90 Inhibition is Effective in Breast Cancer: A Phase 2 Trial of Tanespimycin (17AAG) plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clin. Cancer Res. 2011, 17:5132-5139.

http://dx.doi.org/10.1158/1078-0432.CCR-11-0072

PMid:21558407

Richardson P, Chanan-Khan A, Lonial S, Krishnan AY, Carroll M, Alsina M, Albitar M, Berman D, Messina M, Anderson K: Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Bri. J. Hematol. 2011, 153:729-740.

http://dx.doi.org/10.1111/j.1365-2141.2011.08664.x

PMid:21534941

PressRelease B-MSHDoTaf, http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/ i.

Gao Z, Garcia-Echeverria C, Jensen MR: Hsp90 inhibitors: Clinical development and future opportunities in oncology therapy. Curr. Opin. Drug Di. De. 2010, 13:193-202.

PMid:20205053

Sharma SV, Agatsuma T, Nakano H: Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16:2639-2645.

http://dx.doi.org/10.1038/sj.onc.1201790

PMid:9632140

Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, et al.: The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:3338-3343.

http://dx.doi.org/10.1016/j.bmcl.2005.05.046

PMid:15955698

Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung K-MJ, Collins I, Davies NGM, Drysdale MJ, et al.: 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51:196–218.

http://dx.doi.org/10.1021/jm701018h

PMid:18020435

Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, Brandon AH, Gowan S, Boxall F, et al.: NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68:2850-2860.

http://dx.doi.org/10.1158/0008-5472.CAN-07-5256

PMid:18413753

Novartis: Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients, from http://clinicaltrials.gov/ct2/show/NCT00526045?term=AUY922&rank=8, in Verified May 2013.

Novartis: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab, from http://clinicaltrials.gov/ct2/show/NCT01271920?term=AUY922&rank=10, in Verified October 2012.

Novartis: Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer, from http://clinicaltrials.gov/ct2/show/NCT01259089?term=AUY922&rank=12, in Verified May 2013.

Goldman J, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS: A Phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. J. Clin. Oncol. 2010, 28.

Wong K, Koczywas M, Goldman JW, Paschold EH, Horn L, Lufkin JM, Blackman RK, Teofilovici F, Shapiro G, Socinski MA: An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2011, 29:Abstract 7500.

Corp. SP: Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer. available from: http://clinicaltrials.gov/ct2/show/NCT01348126?term=sta9090+and+docetaxel&rank=3, in, Verified June 2012. 2011.

Modi S: Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer. available from: http://clinicaltrials.gov/ct2/show/NCT01273896?term=STA-9090+and+breast&rank=1, in, Verified October 2012.

Pharma KHK: A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma, from http://clinicaltrials.gov/ct2/show/NCT00457782?term=KW2478&rank=2, in Verified January 2011.

Pharma. KHK: A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma. available from: http://clinicaltrials.gov/ct2/show/NCT01063907, in, Verified April, 2013.

Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, Cosme J, Graham B, Day PJ, Downham R, et al.: Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. J. Med. Chem 2010, 53:5956-5969.

http://dx.doi.org/10.1021/jm100060b

PMid:20662534

Murray CW, Carr MG, Callaghan O, Chessari G, Congreve M, Cowan S, Coyle JE, Downham R, Figueroa E, Frederickson M, et al.: Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. J. Med. Chem. 2010, 53:5942-5955.

http://dx.doi.org/10.1021/jm100059d

PMid:20718493

Shapiro G: Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors. http://clinicaltrials.gov/ct2/show/NCT00878423?term=AT13387&rank=5, in, Verified, May 2013.

Demetri G: A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST. available from: http://clinicaltrials.gov/ct2/show/NCT01294202?term=AT-13387&rank=1, in, Verified May, 2013

Chene P: ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discov. 2002, 1:665-673.

http://dx.doi.org/10.1038/nrd894

PMid:12209147

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, et al.: Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA. 2009, 106:8368-8373.

http://dx.doi.org/10.1073/pnas.0903392106

PMid:19416831 PMCid:PMC2688867

Cerchietti LC, E.C. L, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, et al.: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 2009, 15:1369-1376.

http://dx.doi.org/10.1038/nm.2059

PMid:19966776 PMCid:PMC2805915

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, et al.: HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 2010, 120:3578-3593.

http://dx.doi.org/10.1172/JCI42442

PMid:20852385 PMCid:PMC2947224

Kummar S: A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma. available from: http://bethesdatrials.cancer.gov/clinical-research/search_detail.aspx?ProtocolID=NCI-11-C-0150, in, Verfied January 2013.

Elfiky A, Saif MW, Beeram M, O'Brien S, Lammanna N, Castro JE, Woodworth J, Perea R, Storgard C, Von Hoff DD: BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. . J. Clin. Oncol. 2008, 26:Abstract 2503.

Modi S, Ismail-Khan R, Munster P, Lucas M, Galluppi G, Tangri S, Chen Y, Yamashita M, Storgard CM, Moulder SX: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer. . CTRCAACR San Antonio Breast Cancer Symposium 2010.

Mitchell P: Biogen Idec restructures, sharpens neurology focus. Nat. Biotech. 2011, 29:7-8.

http://dx.doi.org/10.1038/nbt0111-7

PMid:21221080

Yu M, Samlowski WE, Baichwal V, Brown B, Evans BA, Woodland D, Mather G, Patnaik A, Tolcher AW, Papadopoulos K: MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients. J. Clin. Oncol. 2010, 28 Abstract e13112.

Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, et al.: Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer. Mol. Cancer Ther. 2009, 8:3296-3306.

http://dx.doi.org/10.1158/1535-7163.MCT-09-0538

PMid:19952121

van Ingen H, Sanlaville Y: Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma. available from: http://clinicaltrials.gov/ct2/show/NCT01168752?term=debio&rank=3, in, Verified September, 2013

Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, Foley B, Hu M, Partridge JM, Rice J, Scott A, et al.: Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90. Chemistry and Biology 2010, 17:686-694.

http://dx.doi.org/10.1016/j.chembiol.2010.04.015

PMid:20659681

Bryson J, Infante JR, Ramanathan RK, Jones SF, Von Hoff DD, Burris HA: A Phase 1 doseescalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. . J. Clin. Oncol. 2008, 26:Abstract 14613.

Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, et al.: A Phase1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Clin. Cancer Res. 2011, 17:6831-6839.

http://dx.doi.org/10.1158/1078-0432.CCR-11-0821

PMid:21908572 PMCid:PMC3207004

Novartis: A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors. available from: http://clinicaltrials.gov/ct2/show/NCT00879905?term=HSP990&rank=1, in, Verified October 2012.

Novartis: Dose Escalation of HSP990 in Japan/Korea. available from: http://clinicaltrials.gov/ct2/show/NCT01064089?term=HSP990&rank=2, verified December 2012.




DOI: http://dx.doi.org/10.14259%2Fcs.v1i2.62

Refbacks

  • There are currently no refbacks.